StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7780.TW$17.60+0.00%
Fair $17.60+0.0%

7780.TW

Daiken Biomedical Co., Ltd.

Consumer Defensive / Packaged FoodsTaiwan

$17.60

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $17.60Fund rank 33/100 · Data gapFallback financials|
SA 52/C
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $105.2M · quality 67.0/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 57/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 7780.TWLocal privado en este navegador · Daiken Biomedical Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$14.2B

P/E

352.0x

↑

EV/EBITDA

28.6x

↑

ROE

6.2%

↓

Gross Margin

63.6%

↑

Debt/Equity

0.02

↓
52-Week Range$18
$16$192

TradingView lightweight chart

7780.TW price, volumen y niveles de valoración

Último $17.60Periodo -1.7%
Fair value: $17.60

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+28.9%

FCF CAGR

+86.4%

FCF margin

14.2%

FCF / Net income

0.80x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.90B · net income $337.9M · FCF $268.8M

2022-FY → 2025-FY

Gross margin

63.6%-5.7% pts

Operating margin

15.2%+2.5% pts

Net margin

17.8%+7.6% pts

FCF margin

14.2%+9.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.90B$1.90B$1.36B$1.19B$885.0M
Net Income$337.9M$337.9M$106.6M$160.4M$90.2M
EBITDA$425.0M$425.0M$149.8M$199.6M$110.8M
EPS——0.020.710.58
Gross Margin63.6%63.6%62.8%68.4%69.3%
Operating Margin15.2%15.2%11.0%17.1%12.7%
Net Margin17.8%17.8%7.8%13.5%10.2%
Balance Sheet
Debt/Equity0.020.020.001.150.61
Current Ratio10.9310.93———
Cash Flow
Free Cash Flow$268.8M$268.8M$48.5M$105.2M$41.5M
Returns
ROE6.2%6.2%8.2%64.8%39.6%
Valuation
P/E352.00352.00733.33——
EV/EBITDA28.5728.57508.28——
P/B2.622.6259.13——
Growth & Yield
Revenue Growth39.1%39.1%14.4%34.5%—
EPS Growth——-96.6%23.1%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +11.9%

Total return

+11.9%

Start / end P/E

n/dx → n/dx

EPS bridge

0.02 → n/d

Residual

+10.0%

EPS growthn/d
Multiple reratingn/d
Dividend+1.9%
Residual / FX / buybacks / cross-term+10.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.